109 related articles for article (PubMed ID: 23200910)
1. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.
Zappacosta R; Caraceni D; Ciccocioppo L; Rotondo T; Capanna S; Gatta DM; D'Angelo C; Rosini S
Gynecol Oncol; 2013 Mar; 128(3):427-32. PubMed ID: 23200910
[TBL] [Abstract][Full Text] [Related]
2. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
[TBL] [Abstract][Full Text] [Related]
3. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
[TBL] [Abstract][Full Text] [Related]
4. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
[TBL] [Abstract][Full Text] [Related]
6. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.
Uijterwaal MH; Witte BI; Van Kemenade FJ; Rijkaart D; Ridder R; Berkhof J; Balfoort-van der Meij GA; Bleeker MC; Snijders PJ; Meijer CJ
Br J Cancer; 2014 Mar; 110(6):1579-86. PubMed ID: 24518601
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
Waldstrøm M; Christensen RK; Ørnskov D
Cancer Cytopathol; 2013 Mar; 121(3):136-45. PubMed ID: 22987560
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
9. Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS.
Zhu Y; Ren C; Yang L; Zhang X; Liu L; Wang Z
BMC Cancer; 2019 Mar; 19(1):271. PubMed ID: 30917784
[TBL] [Abstract][Full Text] [Related]
10. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.
Wentzensen N; Fetterman B; Castle PE; Schiffman M; Wood SN; Stiemerling E; Tokugawa D; Bodelon C; Poitras N; Lorey T; Kinney W
J Natl Cancer Inst; 2015 Dec; 107(12):djv257. PubMed ID: 26376685
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men.
Silling S; Kreuter A; Hellmich M; Swoboda J; Pfister H; Wieland U
J Clin Virol; 2012 Apr; 53(4):325-31. PubMed ID: 22261122
[TBL] [Abstract][Full Text] [Related]
12. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy.
Sørbye SW; Arbyn M; Fismen S; Gutteberg TJ; Mortensen ES
PLoS One; 2011; 6(10):e26022. PubMed ID: 21998748
[TBL] [Abstract][Full Text] [Related]
13. Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening.
Gustinucci D; Giorgi Rossi P; Cesarini E; Broccolini M; Bulletti S; Carlani A; D'angelo V; D'amico MR; Di Dato E; Galeazzi P; Malaspina M; Martinelli N; Spita N; Tintori B; Giaimo MD; Passamonti B
Am J Clin Pathol; 2016 Jan; 145(1):35-45. PubMed ID: 26712869
[TBL] [Abstract][Full Text] [Related]
14. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
15. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and diagnostic validity of p16/Ki-67, HPV E6/E7 mRNA, and HPV DNA in women with ASCUS: a follow-up study.
Ren C; Zhu Y; Yang L; Zhang X; Liu L; Wang Z; Jiang D
Virol J; 2019 Nov; 16(1):143. PubMed ID: 31752941
[TBL] [Abstract][Full Text] [Related]
19. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
20. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA.
Coquillard G; Palao B; Patterson BK
Gynecol Oncol; 2011 Jan; 120(1):89-93. PubMed ID: 20950847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
